Literature DB >> 8033807

Incretin hormones regulate glucose-dependent insulin secretion in RIN 1046-38 cells: mechanisms of action.

C Montrose-Rafizadeh1, J M Egan, J Roth.   

Abstract

Glucagon-like peptide-1-(7-36) amide (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are known incretin hormones, released from enteroendocrine cells in response to food, that enhance insulin secretion, but only in the presence of elevated blood glucose. We used a rat insulinoma cell line, RIN 1046-38, to study the mechanisms underlying the interaction of incretins and glucose. We measured insulin secretion using RIA and the reverse hemolytic plaque assay. GLP-1 stimulates insulin secretion, with a half-maximal concentration of 34 pM. GLP-1 is approximately 2 orders of magnitude more potent than GIP. GLP-1 and GIP have additive effects at submaximal concentrations, but probably not at maximal concentrations, suggesting a common signal transduction pathway. The glucose requirement for GLP-1 action can be replaced by cell membrane depolarization (20 mM KCl in the extracellular medium), suggesting that a rise of intracellular Ca2+ may be an early step required for GLP-1 action. GLP-1 stimulates insulin secretion by significantly increasing the maximum rate of insulin secretion from 10.3 +/- 2.25 to 25.2 +/- 2.94 ng insulin/mg protein.h. GLP-1 acts by recruiting 1.5-fold more cells to secrete insulin as well as enhancing insulin secretion by individual cells. Combinations of stimuli, such as glucose, cell membrane depolarization, and GLP-1, can recruit 90% of RIN 1046-38 cells to secrete insulin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8033807     DOI: 10.1210/endo.135.2.8033807

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  8 in total

1.  Blockade of cannabinoid 1 receptor improves GLP-1R mediated insulin secretion in mice.

Authors:  Isabel González-Mariscal; Susan M Krzysik-Walker; Wook Kim; Michael Rouse; Josephine M Egan
Journal:  Mol Cell Endocrinol       Date:  2015-12-25       Impact factor: 4.102

2.  Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats.

Authors:  Y Wang; R Perfetti; N H Greig; H W Holloway; K A DeOre; C Montrose-Rafizadeh; D Elahi; J M Egan
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

3.  Desensitization of glucagon-like peptide 1 receptors in insulin-secreting beta TC3 cells: role of PKA-independent mechanisms.

Authors:  J Gromada; S Dissing; P Rorsman
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

Review 4.  Mechanisms of action of glucagon-like peptide 1 in the pancreas.

Authors:  Máire E Doyle; Josephine M Egan
Journal:  Pharmacol Ther       Date:  2006-12-28       Impact factor: 12.310

Review 5.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

Review 6.  GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence.

Authors:  A R Meloni; M B DeYoung; C Lowe; D G Parkes
Journal:  Diabetes Obes Metab       Date:  2012-08-01       Impact factor: 6.577

7.  Signalling pathways activated by glucagon-like peptide-1 (7-36) amide in the rat heart and their role in protection against ischaemia.

Authors:  B Huisamen; S Genade; A Lochner
Journal:  Cardiovasc J Afr       Date:  2008 Mar-Apr       Impact factor: 1.167

Review 8.  An Autonomous Cannabinoid System in Islets of Langerhans.

Authors:  Kanikkai Raja Aseer; Josephine M Egan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-05       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.